Denosumab for Elderly Men with Osteoporosis: A Cost-Effectiveness Analysis from the US Payer Perspective

Table 6

10-year risk of events: base-case.

	Hip fractures	Vertebral fractures	NHNV fractures
Denosumab	0.138	0.101	0.232
Generic alendronate	0.162	0.117	0.229
Zoledronate	0.165	0.097	0.217
Risedronate	0.170	0.115	0.227
Ibandronate	0.176	0.113	0.235
Teriparatide	0.147	0.112	0.216